BMJ Investigation Shines Light on Semaglutide U.K. Marketing

December 18, 2023

Is Pharma Ready for the Age of Autonomous Work?

June 16, 2026

AstraZeneca Invests $85M in Quell for “One and Done” Cell Therapy to Combat Type 1 Diabetes

June 13, 2023

Must Read

Altimmune Reports Phase 2 Pemvidutide Results in Alcohol Use Disorder

July 28, 2026

Included Health Agrees to Acquire Firefly Health to Expand Employer Health Plan Alternatives

July 28, 2026

The Workforce Challenge Facing Biopharma Manufacturing

July 28, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Summit and Akeso Report Updated HARMONi Survival Data for Ivonescimab in Western NSCLC Patients

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Biogen’s Phase 2 Diranersen Data Shows Reduced Cognitive Decline in Alzheimer’s Disease

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Altimmune Reports Phase 2 Pemvidutide Results in Alcohol Use Disorder

Sanofi Ends Amlitelimab Development in Atopic Dermatitis After Phase 3 Program Review

J&J’s Bispecific Combination Works Wonders on Myeloma Progression in Phase 3 Study

Due to poor phase 2 data, Agios declares goodbye to the sickle cell program

Included Health Agrees to Acquire Firefly Health to Expand Employer Health Plan Alternatives

Argenx purchases Forte for $2.2 billion to enter the hands-on phase two-stage medication for vitiligo

Tempus purchases a specialist in cancer genomics in a $1.5 billion deal: Personalis

J&J’s OTTAV Robotic Surgical System has received FDA market authorization in the U.S.

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

J&J MedTech presents the first Ottava surgical robot clinical cases

The Workforce Challenge Facing Biopharma Manufacturing

What Pharma Leaders Are Prioritizing in 2026

How RNA Therapeutics Are Expanding Beyond Rare Diseases

The Future of AI-Assisted Clinical Operations

Tag: Ivonescimab

Ivonescimab Shows 26% Reduction in Death Risk for EGFR-Mutated NSCLC Patients in Phase 3 Trial

Editor Picks

BMJ Investigation Shines Light on Semaglutide U.K. Marketing

Is Pharma Ready for the Age of Autonomous Work?

AstraZeneca Invests $85M in Quell for “One and Done” Cell Therapy to Combat Type 1 Diabetes

Must Read

Altimmune Reports Phase 2 Pemvidutide Results in Alcohol Use Disorder

Included Health Agrees to Acquire Firefly Health to Expand Employer Health Plan Alternatives

The Workforce Challenge Facing Biopharma Manufacturing

Hot Topics

About Us

Follow Us